Ads
related to: newest antipsychotics on the marketconsumerhippo.com has been visited by 100K+ users in the past month
explorefrog.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Antipsychotics can cause weight gain, drowsiness, metabolic syndrome, which can increase risk of heart attack or stroke, or involuntary movements such as blinking or sticking out your tongue.
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
Antipsychotics typically worsen symptoms in people with depersonalisation disorder. [137] Antipsychotic polypharmacy (prescribing two or more antipsychotics at the same time for an individual) is a common practice but not evidence-based or recommended, and there are initiatives to curtail it.
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.
Ads
related to: newest antipsychotics on the marketconsumerhippo.com has been visited by 100K+ users in the past month
explorefrog.com has been visited by 10K+ users in the past month